Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Acorda Therapeutics, Inc. - Common Stock
(NQ:
ACOR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acorda Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Acorda Therapeutics Announces Delisting from Nasdaq
April 15, 2024
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Nasdaq Delisting Notification
April 03, 2024
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
April 01, 2024
From
Acorda Therapeutics
Via
Business Wire
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
April 01, 2024
From
Acorda Therapeutics Acorda Therapeutics, Inc.
Via
Business Wire
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
March 25, 2024
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
January 11, 2024
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
November 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
November 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Inc. (NASDAQ: ACOR) Leading the Way in Thursday Trading Based on Percentage Gain
October 05, 2023
Via
Investor Brand Network
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
August 02, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
August 01, 2023
From
Acorda Therapeutics
Via
Business Wire
Tom Burns Elected to the Acorda Therapeutics Board of Directors
June 28, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 26, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
June 02, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
May 31, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
May 30, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
May 10, 2023
From
Acorda Therapeutics
Via
Business Wire
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
May 09, 2023
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which...
Via
FinancialNewsMedia
Topics
Intellectual Property
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
May 08, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
May 04, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
April 24, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
April 03, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
March 27, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Acorda Therapeutics
Via
Business Wire
ESTEVE Launches INBRIJA® in Spain
March 07, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
March 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
February 14, 2023
From
Acorda Therapeutics
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
